[AKBA] Akebia Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 325.49 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 10.6 Change: 0.51 (5.05%)
Ext. hours: Change: 0 (0%)

chart AKBA

Refresh chart

Strongest Trends Summary For AKBA

AKBA is in the long-term down -69% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Fundamental Ratios
Shares Outstanding37.98 M EPS-4.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.48
P/E To EPS Growth P/S P/BV3.44 Price/Cash Per Share3.24
Price/Free Cash Flow ROA-36.76% ROE-40.2% ROI
Current Ratio11.62 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities50 K Cash From Investing Activities3.4 M Cash From Operating Activities-8.35 M Gross Profit
Net Profit-10.7 M Operating Profit-10.79 M Total Assets103.46 M Total Current Assets102.69 M
Total Current Liabilities8.84 M Total Debt Total Liabilities8.85 M Total Revenue
Technical Data
High 52 week18.15 Low 52 week5.39 Last close6.18 Last change0.65%
RSI54.95 Average true range0.43 Beta1.18 Volume394.84 K
Simple moving average 20 days3.15% Simple moving average 50 days-14.05% Simple moving average 200 days-36.77%
Performance Data
Performance Week-4.92% Performance Month-19% Performance Quart-28.22% Performance Half-35.02%
Performance Year-65.08% Performance Year-to-date11.75% Volatility daily4.97% Volatility weekly11.12%
Volatility monthly22.79% Volatility yearly78.95% Relative Volume2357.44% Average Volume1.01 M
New High New Low


2019-05-09 18:02:54 | Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT

2019-05-09 14:44:25 | Akebia Therapeutics, Inc. AKBA Q1 2019 Earnings Call Transcript

2019-05-09 13:16:36 | Here’s What Hedge Funds Think About Akebia Therapeutics Inc AKBA

2019-05-09 08:10:29 | Akebia Therapeutics: 1Q Earnings Snapshot

2019-05-09 08:00:00 | Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

2019-05-08 11:45:07 | Seth Klarman Keeps Buying This Biotech Stock

2019-05-02 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-02 10:32:02 | Will Akebia Therapeutics AKBA Report Negative Earnings Next Week? What You Should Know

2019-05-02 08:00:00 | Akebia and Otsuka Pharmaceutical Development & Commercialization Inc OPDC Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

2019-04-30 08:00:00 | Akebia Therapeutics to Report First Quarter 2019 Financial Results

2019-04-10 10:30:02 | Akebia Expands Vadadustat Licensing Deal With Vifor Pharma

2019-04-09 01:00:00 | Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement

2019-04-09 01:00:00 | Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement

2019-04-05 16:19:00 | Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference

2019-04-02 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-04-01 08:00:00 | Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders

2019-03-27 07:20:00 | Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy — Fundamental Analysis, Key Performance Indications

2019-03-26 17:48:07 | Akebia Therapeutics Inc AKBA Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-19 01:11:59 | Akebia Therapeutics AKBA Q4 2018 Earnings Conference Call Transcript

2019-03-19 00:15:44 | Edited Transcript of AKBA earnings conference call or presentation 18-Mar-19 8:30pm GMT

2019-03-18 16:05:00 | Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights

2019-03-15 17:25:02 | MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?

2019-03-15 15:55:02 | MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?

2019-03-15 14:24:02 | What Analysts Are Recommending for MannKind and Akebia in March

2019-03-12 16:35:00 | Why Akebia Therapeutics, Momo, and Switch Jumped Today

2019-03-12 11:55:00 | Why Akebia Therapeutics Is Soaring Today

2019-03-12 07:47:54 | The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

2019-03-12 04:00:00 | Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease

2019-03-11 10:30:02 | Analysts Estimate Akebia Therapeutics AKBA to Report a Decline in Earnings: What to Look Out for

2019-03-06 07:00:00 | Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast

2019-03-04 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-02-19 07:18:11 | Akebia Therapeutics, Inc. NASDAQ:AKBA Is Trading At A 29.34% Discount

2019-02-14 17:09:58 | Seth Klarman Disculoses 4th-Quarter Stock Purchases

2019-02-04 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-02-04 07:50:00 | Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International — Future Expectations, Projections Moving into 2019

2019-01-30 09:18:02 | Akebia Therapeutics AKBA Upgraded to Buy: Here's What You Should Know

2019-01-18 09:17:04 | What Did Akebia Therapeutics, Inc.’s NASDAQ:AKBA CEO Take Home Last Year?

2019-01-02 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-01-02 07:00:00 | Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-16 23:36:39 | Hedge Funds Are Crazy About Akebia Therapeutics Inc AKBA

2018-12-14 17:10:11 | Seth Klarman Gains Stake in Akebia Therapeutics

2018-12-14 11:27:29 | Abrams Capital Management’s Return, AUM and Holdings

2018-12-13 16:30:59 | Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger, Raymond James Says

2018-12-13 10:55:00 | Why Akebia Therapeutics Is Soaring Today

2018-12-13 07:00:00 | Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company

2018-12-11 12:00:00 | Akebia Therapeutics Shareholders Approve Merger with Keryx

2018-12-03 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-11-30 08:55:00 | Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics

2018-11-30 08:55:00 | Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx

2018-11-29 08:35:00 | Report: Developing Opportunities within Teleflex, Anthem, Crown Castle International, MSCI, GCI Liberty, and Akebia Therapeutics — Future Expectations, Projections Moving into 2018